Navigation Links
SEQUENOM Announces Launch of MassARRAY Compact 96 System

SAN DIEGO, July 27 /PRNewswire-FirstCall/ -- SEQUENOM, Inc. (Nasdaq: SQNM) today announced the launch of the MassARRAY(R) Compact 96 system.


This generation of the MassARRAY system now addresses the needs of lower throughput laboratories. The combination of features of the new MassARRAY Compact 96 system - accuracy, sensitivity, and now the ability to cost-effectively run fewer samples - make this an ideal system for use in basic and clinical laboratories.

With the addition of the MassARRAY Compact 96 system SEQUENOM now offers genetic analysis solutions to serve the needs of any sized laboratory.

The MassARRAY Compact 96 system delivers:

  • exceptional performance which makes it ideal for the most demanding applications; and
  • highly sensitive and specific mass spec-based detection of low frequency mutations that are typically undetected using conventional techniques.

The technology allows researchers to generate assays against any biomarkers they desire to validate, and to quickly and easily make changes to assays and biomarkers throughout the validation process.

MassARRAY technology supports key genomic applications, including single nucleotide polymorphism (SNP) genotyping, quantitative gene expression, and copy number variation (CNV) analysis, providing a multi-faceted view of a researcher's biological system of interest.

"Replacing other platforms that are limited to looking at tens of samples per week, our range of MassARRAY system products now allows for the analysis of hundreds through thousands of samples per day," said Mike Monko, senior vice president of sales & marketing at SEQUENOM. "MassARRAY technology enables detection of the most common molecular biomarker classes - somatic mutations via the OncoCarta mutation panel, SNPs, CNVs, methylation patterns, expression signatures - with an unmatched combination of quantitative accuracy and sensitivity. This is the type of high data quality that can potentially push biomarkers to clinical utilization and make the promise of personalized medicine a reality."

About MassARRAY

SEQUENOM's proprietary MassARRAY system is a high performance matrix assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry-based nucleic acid analysis platform that quantitatively measures genetic target material and its variations in a rapid, accurate, and cost efficient manner. SEQUENOM's MassARRAY system facilitates a number of nucleic acid analysis applications including SNP genotyping and allelotyping, CNV analysis, quantitative gene expression analysis, quantitative methylation marker analysis, comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control.


SEQUENOM is a life sciences company committed to providing the best genetic analysis products that translate the results of genomic science into solutions for molecular diagnostics, biomedical research, translational research and molecular medicine applications. As an industry innovator in DNA analysis technology, SEQUENOM's MassARRAY system allows a direct mass measurement of nucleic acids, providing unparalleled precision and quantification. On the diagnostics front, SEQUENOM is developing a comprehensive portfolio of prenatal test methods by combining the versatility of the MassARRAY system with the company's SEQureDx(TM) technology, which enables the detection of circulating cell-free fetal nucleic acids in a maternal blood sample. The company is also developing tests for oncology, infectious diseases and other disorders. The company was founded in 1994 and is headquartered in San Diego, California. For more information please visit

SEQUENOM(R), SEQureDx(TM), and MassARRAY(R) are trademarks of SEQUENOM, Inc. All other trademarks and service marks are the property of their respective owners.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the performance of the MassARRAY Compact 96 system, the potential for clinical utilization of biomarkers, the promise of personalized medicine, and the Company's development of prenatal test methods and tests for oncology, infectious diseases and other disorders, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use by customers of new products such as the MassARRAY Compact 96 system, the Company's ability to develop and commercialize new technologies and products, particularly new technologies such as noninvasive prenatal and other diagnostics and laboratory developed tests, reliance upon the collaborative efforts of other parties, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, the independent investigation and other risks detailed from time to time in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30
2. Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
3. Sequenom to Webcast Analyst and Investor Briefing Presentation on June 3
4. Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24
5. Human Genome Sciences Announces Proposed Public Offering of Common Stock
6. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
7. Sechrist Industries, World Leader in Hyperbaric Chambers, Announces Edward Pulwer as President/CEO
8. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
9. PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group
10. Spectrum Announces Fetal Bovine Serum Product Line
11. Cell Therapeutics, Inc. Announces Exercise of Overallotment
Post Your Comments:
(Date:12/1/2015)...  Symic, a clinical-stage biotherapeutics company developing multiple compounds ... announced that it has secured $25 million in a ... its lead candidates SB-030 and SB-061. The financing was ... all existing major investors, as well as several new ... by Symic to over $43 million since being founded ...
(Date:12/1/2015)... Texas (PRWEB) , ... December 01, 2015 , ... Matthew ... his new post, VerMilyea will oversee all IVF lab procedures as well ... and fertility preservation. , “We traveled 7,305 miles to Auckland, New Zealand to bring ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group ... in the Santiago Marriott. The Global Stem Cells Group GMP facility is equipped ... of qualified medical researchers and practitioners, experienced in administering stem cell protocols using ...
(Date:11/30/2015)... -- Partnership includes an MPP ... the u niversity , s Solid Drug ... cale - up through ... Africa , where licensees based anywhere in the world will have the right ... Africa , where licensees based anywhere in the world will have ...
Breaking Biology Technology:
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
(Date:10/29/2015)... 2015  Connected health pioneer, Joseph C. Kvedar ... technology-enabled health and wellness, and the business opportunities that ... The Internet of Healthy Things . Long before ... existed, Dr. Kvedar, vice president, Connected Health, Partners HealthCare, ... moving care from the hospital or doctor,s office into ...
(Date:10/27/2015)... 27, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... Google has adopted the Synaptics ® ClearPad ® ... power its newest flagship smartphones, the Nexus 5X by ... --> --> Synaptics works ... strategic collaboration in the joint development of next generation ...
Breaking Biology News(10 mins):